Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025
Rhea-AI Summary
Anteris Technologies (NASDAQ: AVR) announced that one-year clinical outcomes for the DurAVR® Transcatheter Heart Valve (THV) will be presented at TCT 2025 on October 27, 2025 at 2:27pm GMT-7 in the Innovation Theater, Moscone Center, San Francisco.
The oral presentation, titled “The DurAVR® Biomimetic TAVR System in Patients with Small Aortic Annuli (Anteris): One-Year Clinical and Hemodynamic Outcomes,” summarizes outcomes in over 100 patients with symptomatic severe aortic stenosis and small aortic annuli (annulus area 396 ± 37 mm2). The company said the outcomes to date are encouraging and will be further evaluated in the global pivotal PARADIGM Trial, a prospective randomized controlled trial comparing DurAVR THV to commercially available TAVRs for safety and effectiveness.
Positive
- None.
Negative
- None.
News Market Reaction 14 Alerts
On the day this news was published, AVR gained 4.60%, reflecting a moderate positive market reaction. Argus tracked a peak move of +99.0% during that session. Argus tracked a trough of -20.1% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $9M to the company's valuation, bringing the market cap to $193M at that time. Trading volume was exceptionally heavy at 8.2x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that one-year clinical outcomes with the DurAVR® Transcatheter Heart Valve (THV) will be presented by Rishi Puri MD PhD, at TCT® 2025 – The 37th Annual Transcatheter Cardiovascular Therapeutics® Conference, taking place in San Francisco, California, October 25-28, 2025.
An oral presentation is scheduled for Monday, October 27 (2:27pm GMT-7) in the Innovation Theater, Hall E, Exhibition Level, Moscone North, Moscone Center, as part of “Innovation Session 11: Emerging Concepts and Technologies in TAVR”, entitled “The DurAVR® Biomimetic TAVR System in Patients with Small Aortic Annuli (Anteris): One-Year Clinical and Hemodynamic Outcomes”. The presentation focuses on one-year clinical outcomes for the DurAVR® THV in symptomatic severe aortic stenosis patients with small aortic annuli (aortic annulus area 396 + 37 mm2).
The encouraging clinical outcomes observed to date in over 100 patients implanted with the DurAVR® THV will be further evaluated in the Company’s global pivotal trial (the “PARADIGM Trial”). The PARADIGM Trial is a prospective randomized controlled trial (RCT) which will evaluate the safety and effectiveness of the DurAVR® THV compared to commercially available transcatheter aortic valve replacements (TAVRs) in the treatment of severe aortic stenosis.
About Anteris
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
Anteris’ lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.
Forward-Looking Statements
This announcement contains forward-looking statements, including statements regarding the results of the PARADIGM Trial and the contours of the PARADIGM Trial. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2024 that was filed with the SEC and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
For more information:
| Investor Relations | Investor Relations (US) | |
| investor@anteristech.com | mchatterjee@bplifescience.com | |
| Debbie Ormsby | Malini Chatterjee, Ph.D. | |
| Anteris Technologies Global Corp. | Blueprint Life Science Group | |
| +61 1300 550 310 | +61 7 3152 3200 | +1 917 330 4269 | |
| Website | www.anteristech.com | |
| X | @AnterisTech | |
| https://www.linkedin.com/company/anteristech | ||
FAQ
When will Anteris (AVR) present DurAVR one-year outcomes at TCT 2025?
What patient group is included in the DurAVR one-year clinical outcomes for AVR?
How many patients are included in the DurAVR one-year outcomes presented by AVR?
What is the PARADIGM Trial mentioned by Anteris (AVR)?
Where and in which session will Anteris (AVR) present the DurAVR results at TCT 2025?
Do the DurAVR one-year outcomes reported by Anteris (AVR) include specific efficacy or safety numbers?
